From Startup Aduro Biotech
Link to Full Article: http://investors.aduro.com/phoenix.zhtml?c=242043&p=irol-newsArticle&ID=2368930
BERKELEY, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) — Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the following upcoming investor conferences:
Cantor Fitzgerald 2018 Global Healthcare Conference in New York, NY on Tuesday, October 2, 2018 at 3:25pm Eastern Time
Leerink Partners Roundtable Series: Rare Disease & Oncology in New York, NY on Wednesday, October 3, 2018 at 8:00am Eastern Time
To access the live webcast and subsequent archived recording of this and other company presentations, please visit Aduro’s website at www.aduro.com.
About Aduro Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that are intended to transform the treatment of challenging diseases. Aduro’s technology platforms, which are designed to harness the body’s natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro’s STING pathway activator platform is designed to activate the STING receptor in immune cells, which may result in a potent tumor-specific immune response. ADU-S100 (MIW815) is the first STING pathway activator compound to enter the clinic and is currently being evaluated in a Phase 1 clinical trial as a single agent and in combination with ipilimumab and in a Phase 1b combination trial with spartalizumab (PDR001), an investigational anti-PD1 immune checkpoint inhibitor. Aduro’s B-select monoclonal antibody platform, including BION-1301, an anti-APRIL antibody, is comprised of a number of immune modulating assets in research and development. Aduro’s pLADD program is based on proprietary attenuated strains of Listeria that have been engineered to express tumor neoantigens that are specific to an individual patient’s tumor. Other Listeria strains for lung and prostate cancers are being advanced by a partner. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.
Chief Financial Officer
Aduro Biotech, Inc.
Please visit their site for more information: Aduro Biotech.com
All,Biotechnology,Healthcare News,Startup News